Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers
K. N. Rose(Harvard University), Stephen N. Gomperts(Harvard University), Aline Fassini(Harvard University), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Sung‐Han Lin(Massachusetts General Hospital), M. A. Schwarzschild(Harvard University), Xiaonan Xue(Albert Einstein College of Medicine), Wenli Cai(Massachusetts General Hospital), Musa Zorlu(Massachusetts General Hospital)
Cited by 3
Related Papers
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833
Research criteria for the diagnosis of prodromal dementia with Lewy bodies
|Neurology|2020|772
Validating novel tau positron emission tomography tracer <scp>[F‐18]‐AV‐1451 (T807)</scp> on postmortem brain tissue
|Annals of Neurology|2015|626